Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 108,829
  • Shares Outstanding, K 29,255
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,940 K
  • 60-Month Beta 2.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.22
Trade ZYNE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.43
  • Number of Estimates 3
  • High Estimate -0.40
  • Low Estimate -0.45
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -437.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +17.72%
on 09/24/20
4.46 -16.59%
on 10/15/20
+0.47 (+14.46%)
since 09/23/20
3-Month
3.16 +17.72%
on 09/24/20
4.46 -16.59%
on 10/15/20
+0.06 (+1.64%)
since 07/23/20
52-Week
2.55 +45.88%
on 03/17/20
8.54 -56.44%
on 10/25/19
-4.62 (-55.40%)
since 10/23/19

Most Recent Stories

More News
Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster...

ZYNE : 3.72 (+2.48%)
New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster...

ZYNE : 3.72 (+2.48%)
Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the...

ZYNE : 3.72 (+2.48%)
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced...

ZYNE : 3.72 (+2.48%)
Medical Cannabis Legalization Helps Destigmatize Related Products

, /PRNewswire/ -- Presently, the medical cannabis sector accounts for the majority of the market share, and progress is slowly being made in removing the stigmas associated with such products. For example,...

ACB.TO : 6.13 (-3.62%)
ZYNE : 3.72 (+2.48%)
LABS.TO : 0.84 (unch)
MEDIF : 0.6444 (+1.48%)
TLRY : 6.73 (-1.46%)
Legalization Efforts Continue to Drive the Cannabis Market Growth

, /PRNewswire/ -- The legalization of cannabis in several countries is one of the key factors driving the market's growth. In addition, the use of cannabis for medical purposes is gaining momentum worldwide....

OGI : 1.2600 (+0.80%)
MEDIF : 0.6444 (+1.48%)
LABS.TO : 0.84 (unch)
HEXO : 0.7692 (+2.03%)
ZYNE : 3.72 (+2.48%)
GWPH : 95.00 (-2.10%)
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%

Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ACST : 0.2070 (+3.24%)
ZYNE : 3.72 (+2.48%)
Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 3.72 (+2.48%)
Zynerba Pharmaceuticals Provides Update on Recent Milestones

- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel(TM) in Children and Adolescents with Fragile X Syndrome and a Fully Methylated...

ZYNE : 3.72 (+2.48%)
Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 3.72 (+2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 3.87
1st Resistance Point 3.80
Last Price 3.72
1st Support Level 3.62
2nd Support Level 3.51

See More

52-Week High 8.54
Fibonacci 61.8% 6.25
Fibonacci 50% 5.55
Fibonacci 38.2% 4.84
Last Price 3.72
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar